SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-17-018076
Filing Date
2017-08-25
Accepted
2017-08-25 16:12:19
Documents
4
Period of Report
2017-09-27
Effectiveness Date
2017-08-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A kalv-def14a_20170927.htm DEF 14A 851914
2 GRAPHIC g2017082422273986516687.jpg GRAPHIC 89793
3 GRAPHIC g2017082422273981816685.jpg GRAPHIC 43044
4 GRAPHIC g2017082422273983616686.jpg GRAPHIC 64190
  Complete submission text file 0001564590-17-018076.txt   1125080
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: DEF 14A | Act: 34 | File No.: 001-36830 | Film No.: 171052109
SIC: 2834 Pharmaceutical Preparations